According to the Zhitong Finance App, Junshengtai Pharmaceutical-B (02511) announced its 2026 interim results. Other revenue was 3.304 million yuan, a year-on-year decrease of 68.66%; losses attributable to the company's owners were about 146 million yuan, an increase of 21.43% over the previous year; and a loss of 0.29 yuan per share.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.